Compare · RAIN vs TMO
RAIN vs TMO
Side-by-side comparison of Rain Enhancement Technologies Holdco Inc. (RAIN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- RAIN operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $222.03B, about 21375.4x RAIN ($10.4M).
- TMO has been more active in the news (16 items in the past 4 weeks vs 11 for RAIN).
- TMO has more recent analyst coverage (25 ratings vs 8 for RAIN).
- Company
- Rain Enhancement Technologies Holdco Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $10.4M
- $222.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 16
- Recent ratings
- 8
- 25
Rain Enhancement Technologies Holdco Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RAIN
- Rain Enhancement Technologies Announces Agreement with California Highway Patrol to Test Fog Mitigation Technology
- Rain Enhancement Technologies Holdco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Amendment: Chief Executive Officer Seidl Randy bought $104,225 worth of shares (110,000 units at $0.95), increasing direct ownership by 17% to 754,834 units (SEC Form 4)
- Rain Enhancement Technologies Recognized With 2026 "AgTech Climate Innovation of the Year" by AgTech Breakthrough
- Chief Executive Officer Seidl Randy bought $104,225 worth of shares (110,000 units at $0.95), increasing direct ownership by 17% to 754,834 units (SEC Form 4)
- SEC Form 10-Q filed by Rain Enhancement Technologies Holdco Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Rain Enhancement Technologies Holdco Inc.
- Amendment: SEC Form 3 filed by new insider Warsh Alexandra
- Amendment: SEC Form 3 filed by new insider Steele Alexandra
- Amendment: Chief Executive Officer Seidl Randy bought $100,949 worth of shares (42,514 units at $2.37), increasing direct ownership by 7% to 644,834 units (SEC Form 4)
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)